Viewers of Mad Money enjoy the "Lightning Round" segment of the show. This is when callers can ask Jim Cramer about stocks they are interested in. One caller Tuesday night asked about TG Therapeutics (TGTX) : "Do not sell this stock. I love what they're doing," replied Cramer.
Let's check out the charts and the indicators of this biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
In this daily bar chart of TGTX, below, we can see that prices declined with the broad market losses from February into the middle of March. From that March nadir prices have soared to the $32 area from near just $6. The slope of the 50-day moving average line is positive and so is the 200-day moving average line.
The On-Balance-Volume (OBV) line has risen the past 12 months to confirm the price gains and tell us that buyers of TGTX have been more aggressive.
The Moving Average Convergence Divergence (MACD) has been positive since late April but is currently crossing to the downside for a take profits sell signal.